Since the first clinical trial conducted in 1985 (6), the therapeutic application of IFN-γ has been tested in a variety of malignancies, including melanoma, leukemia, ovarian cancer, renal cell carcinoma, hepatocellular carcinoma, lung cancer, breast cancer, bladder cancer and colorectal cancer (7). This evidence concerns the gene IFNG and urinary bladder carcinoma.